Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-14

Study Completion Date

2021-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyperventilation syndrome is a frequent cause of dyspnea in general population and in respiratory diseases like asthma but has never been studied in pulmonary hypertension. The goal of this study is to measure the prevalence of pulmonary hypertension in a population of patients with controlled pulmonary arterial hypertension (PAH).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Properties of the Hyperventilation Provocation Test for the Diagnosis of the Hyperventilation Syndrome

NCT05100290

Hyperventilation Syndrome

COMPLETED

Adherence of Diuretics in Pulmonary Hypertension

NCT05167968

Precapillary Pulmonary Hypertension

COMPLETED

Monitoring of the Influence of Approved PH-therapies RV-PA Coupling

NCT05935865

Pulmonary Hypertension

RECRUITING

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819

Hypertension High Blood Pressure Ventricular Hypertrophy +2 more

COMPLETED NA

Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension

NCT06079151

Pulmonary Hypertension

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hyperventilation syndrome has been described as a cause of dyspnea in the general population and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics affected. However, Hyperventilation syndrome has never been sought in a population with PAH. Hyperventilation syndrome, although complex pathophysiology, may be simply corrected by a management of respiratory physiotherapy based on the control of respiration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pulmonary arterial hypertension

The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.

Group Type EXPERIMENTAL

Hyperventilation test

Intervention Type DIAGNOSTIC_TEST

The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperventilation test

The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Questionnaire of Nijmegen Questionnaire of Dyspnea Questionnaire of quality of life Questionnaire of screening for psychological disorders

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. - Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4 months.
* Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP \< 300ng/L or Brain Natriuretic Peptide(BNP) \< 50 ng/L and optimal hemodynamic results measured by a right heart catheterization in the last year: right atrial pressure \< 8 mmHg, cardiac index \> 2,5 L/min/m2, veinous saturation in oxygen \> 65%)
* Informed and written consent
* Non-affiliation to a social security

Exclusion Criteria

* Existence of another form of pulmonary hypertension
* Existence of vocal cord dysfunction
* Pregnancy
* Obesity\> stage 2 (BMI 35 kg / m2)
* Age ≥ 75 years

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No